An Open-Label Pilot Study of Methylphenidate in the Treatment of Cocaine Dependent Patients with Adult Attention Deficit/ Hyperactivity Disorder

A multi-site, open-label study of methylphenidate for treating patients with comorbid diagnoses of attention deficit/hyperactivity disorder and cocaine dependence was performed. Forty-one participants, who met DSM-IV criteria for adult attention deficit/hyperactivity disorder and cocaine dependence,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of addictive diseases 2004-01, Vol.23 (1), p.77-92
Main Authors: Somoza, Eugene C., Winhusen, Theresa M., Bridge, T. Peter, Rotrosen, John P., Vanderburg, Douglas G., Harrer, Judy M., Mezinskis, Juris P., Montgomery, Margaret A., Ciraulo, Domenic A., Wulsin, Lawson R., Barrett, Jera A.
Format: Article
Language:English
Subjects:
ADHD
Adult
attention deficit disorder
Attention Deficit Disorder with Hyperactivity - complications
Attention deficit hyperactivity disorder
Central Nervous System Stimulants - therapeutic use
Cocaine
Cocaine dependence
Cocaine-Related Disorders - rehabilitation
Drug addiction
Drug therapy
Female
Humans
Male
methylphenidate
Methylphenidate - therapeutic use
Middle Aged
Pilot Projects
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A multi-site, open-label study of methylphenidate for treating patients with comorbid diagnoses of attention deficit/hyperactivity disorder and cocaine dependence was performed. Forty-one participants, who met DSM-IV criteria for adult attention deficit/hyperactivity disorder and cocaine dependence, were enrolled into this ten week outpatient study. The targeted total daily dose of methylphenidate was 60 mg (20 mg TID). Participants received individual substance abuse therapy throughout the trial. Safety measures included adverse events, vital signs, and electrocardiograms. Methylphenidate's efficacy was assessed by both objective and subjective measures. Seventy percent of the participants completed final study measures. Safety measures indicated that methylphenidate was well tolerated by the participants. Subjective efficacy measures suggested that participants evidenced improvement in both cocaine dependence and adult attention deficit/hyperactivity disorder symptoms. Quantitative benzoylecgonine indicated that only those participants categorized as being compliant showed improvement. A double-blind, placebo-controlled study of methylphenidate for this population may be warranted.
ISSN:1055-0887
1545-0848
DOI:10.1300/J069v23n01_07